GLP-2
Shop GLP-2
Shop GLP-2Code ths10 applied at checkout
Also called: GLP2-2G-10Nle-1K-E -K5
By The Health Stacks Research TeamUpdated September 22, 2026
GLP-2 is a tiny messenger made by your body. It comes from the same parent protein as another well-known messenger called GLP-1. Your gut makes GLP-2 after you eat. It helps the inside wall of your gut stay strong and healthy.
GLP-2's main job is to help the gut lining grow and repair. It also helps your body take in food better. The lab-made copy of this peptide is sold by research companies as a white powder for lab studies only. It is not an approved medicine for people.
Scientists are still learning about GLP-2. Most studies are done in animals or labs, not in large human trials. Long-term safety and the right amounts for people are not settled. Anyone thinking about peptide products should talk to a doctor first.
ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.
Benefits
What GLP-2 Helps With
The benefits people report — backed by research.
Gastrointestinal & gut (25)
Markedly increases small bowel growth 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcInduces hyperplasia of the villus epithelium 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcTreatment of disorders of the alimentary tract or digestive system 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Intestinal growth and adaptation 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces parenteral nutrition/IV fluid requirements in Short Bowel Syndrome 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Increases nutrient absorption and nutritional status 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Trophic effects: increases intestinal villus height and crypt depth 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Anti-inflammatory 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Protects against NSAID-induced intestinal injury 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Protects against intestinal ischemia-reperfusion injury 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Prevents TPN-induced mucosal atrophy 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Intestinotrophic activity promoting small bowel epithelial proliferation 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Stimulation of mucosal growth in the small and large intestine 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Increased nutrient absorption 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction of intestinal permeability 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Intestinotrophic effects and intestinal epithelial cell growth 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →DPP-IV resistant GLP-2 analogues show enhanced in vivo potency 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Gastric / gut lining 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Weight management 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Intestinotrophic growth factor 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →DP IV-resistant GLP-2 analogues show increased in vivo potency 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Sitagliptin enhances intestinal adaptation in short bowel syndrome models 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves nutrient absorption and nutritional status in short-bowel patients with no colon 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Drives adaptive mucosal growth in the small intestine 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Essential component of the mucosal response to bacterial pathogens and disruption of mucosal integrity 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Glycemic & metabolic (3)
Treatment of glucose homeostasis disorders 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →DPP-4 inhibitors potentiate the biological actions of exogenous GLP-2 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Neuroprotection & cognitive (2)
Treatment of neurodegenerative disorders of the central nervous system 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Protects cultured hippocampal cells from glutamate-induced cytotoxicity 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Weight management (2)
Weight management 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Inhibits food intake via central administration in rodents 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
More reported benefits (2)
Skin health 70/100Rated 70/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Bone repair 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Free: The Peptide Stack Cheat-Sheet
You just read the research on GLP-2. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
Self-reported & vendor-suggested
Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.
SubQ
- 50 microg/kg 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Abdominal painModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- HeadacheMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- NauseaMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- VomitingMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- NasopharyngitisMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Abdominal discomfortMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Stomal irritationMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- CholecystitisModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Development of non-neutralizing antibodiesMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased polyp burdenModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Accelerated growth of colonic neoplasmsSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Development of adenocarcinomas and increased aberrant crypt fociSevere 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased proliferation and migration of human colon cancer cellsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Increased circulating levels of glucagonMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Reduced doubling time of colon cancer cell linesModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get GLP-2
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Shop GLP-2
Code ths10 applied at checkout
News
Latest on GLP-2
Dated, sourced reporting that mentions GLP-2.
Regulatory
NuScience Peptides LLC
The FDA issued a warning letter to NuScience Peptides LLC for marketing unapproved injectable peptide drugs, including GLP-1/GLP-2/GLP-3 products and other peptides, on its website. The agency determined these products are unapproved new drugs under the FD&C Act. FDA warned that failure to correct the violations could lead to seizure or injunction.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Regulatory
Peptide Partners LLC
The FDA issued a warning letter to Peptide Partners LLC for marketing unapproved peptide drugs, including semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, and PT-141, via its website. The agency stated these products violate the Federal Food, Drug, and Cosmetic Act as unapproved new drugs. The letter highlights the risks of injectable unapproved products and warns of potential seizure or injunction if violations persist.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Wondering how GLP-2 pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →